+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • July 2024
  • 200 Pages
  • Global
From
Systemic Lupus Erythematosus - Pipeline Insight, 2025 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
From
Lacosamide Injection Market - Global Forecast to 2030 - Product Thumbnail Image

Lacosamide Injection Market - Global Forecast to 2030

  • Report
  • August 2025
  • 198 Pages
  • Global
From
Rheumatoid Arthritis Drugs Market 2024-2028 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Market 2024-2028

  • Report
  • October 2023
  • 162 Pages
  • Global
From
Fibromyalgia - Pipeline Insight, 2025 - Product Thumbnail Image

Fibromyalgia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Krabbe Disease Treatment Market 2024-2028 - Product Thumbnail Image

Krabbe Disease Treatment Market 2024-2028

  • Report
  • June 2024
  • 145 Pages
  • Global
From
From
From
Autoimmune Collaboration and Licensing Deals 2016-2026 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2026

  • Report
  • April 2026
  • 500 Pages +
  • Global
From
Loading Indicator